Literature DB >> 18434562

Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of beta-lactam resistance.

Annarita Mazzariol1, Marco Aldegheri, Marco Ligozzi, Giuliana Lo Cascio, Raffaella Koncan, Roberta Fontana.   

Abstract

A total of 78 isolates of Pseudomonas aeruginosa grouped according to the phenotype for ceftazidime and imipenem susceptibility/resistance were used to assess the accuracy of the Vitek 2 system in antimicrobial susceptibility testing. Comparisons were made with a MIC gradient test for piperacillin-tazobactam, ceftazidime, aztreonam, imipenem, meropenem, gentamicin, and ciprofloxacin. For the total of 546 isolate-antimicrobial combinations tested, the category agreement was 83.6%, with 2.0, 1.6, and 12.8% very major, major, and minor errors, respectively. Vitek 2 accuracy was influenced differently by the mechanism responsible for resistance, and interpretation of the results in relation to phenotype could improve the performance of the system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434562      PMCID: PMC2446835          DOI: 10.1128/JCM.02216-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  C C Sanders; M Peyret; E S Moland; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; J Krzewinski; Z Liu; D Larone; S A Marshall; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001-04       Impact factor: 2.803

3.  Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory.

Authors:  J-L Donay; D Mathieu; P Fernandes; C Prégermain; P Bruel; A Wargnier; I Casin; F X Weill; P H Lagrange; J L Herrmann
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa.

Authors:  J Trias; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

5.  Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate.

Authors:  L Lauretti; M L Riccio; A Mazzariol; G Cornaglia; G Amicosante; R Fontana; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Selection criteria for an antimicrobial susceptibility testing system.

Authors:  J H Jorgensen
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

7.  Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.

Authors:  Mark A Toleman; Doug Biedenbach; David M C Bennett; Ronald N Jones; Timothy R Walsh
Journal:  J Antimicrob Chemother       Date:  2004-12-01       Impact factor: 5.790

8.  Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.

Authors:  R N Jones; D J Biedenbach; S A Marshall; M A Pfaller; G V Doern
Journal:  Diagn Microbiol Infect Dis       Date:  1998-10       Impact factor: 2.803

9.  Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  James A Karlowsky; Mellany K Weaver; Clyde Thornsberry; Michael J Dowzicky; Mark E Jones; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities.

Authors:  G Cornaglia; L Guan; R Fontana; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  4 in total

Review 1.  Expert systems in clinical microbiology.

Authors:  Trevor Winstanley; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints.

Authors:  April M Bobenchik; Eszter Deak; Janet A Hindler; Carmen L Charlton; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-11-23       Impact factor: 5.948

3.  Results of a local combination therapy antibiogram for Pseudomonas aeruginosa isolates: is double worth the trouble?

Authors:  Matthew Song; Thomas J Dilworth; Erik Munson; Jim Davis; Ramy H Elshaboury
Journal:  Ther Adv Infect Dis       Date:  2017-08-23

4.  Rapid disc diffusion antibiotic susceptibility testing for Pseudomonas aeruginosa, Acinetobacter baumannii and Enterococcus spp.

Authors:  Michael Hombach; Marion Jetter; Nicolas Blöchliger; Natalia Kolesnik-Goldmann; Peter M Keller; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.